Synonym
Domiodol; M.G.13608; M.G.-13608; M.G. 13608
IUPAC/Chemical Name
1,3-Dioxolane-4-methanol, 2-(iodomethyl)-
InChi Key
NEIPZWZQHXCYDV-UHFFFAOYSA-N
InChi Code
InChI=1S/C5H9IO3/c6-1-5-8-3-4(2-7)9-5/h4-5,7H,1-3H2
SMILES Code
OCC1OC(CI)OC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
244.03
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fiocchi A, Grasso U, Zuccotti G, Arancio R, Riva E, Giovannini M. Domiodol treatment for bronchopulmonary diseases in the paediatric age group: a double- blind controlled clinical trial versus placebo. J Int Med Res. 1988 Jan- Feb;16(1):31-8. doi: 10.1177/030006058801600103. PMID: 3280363.
2: Kogi K, Konishi K, Saito T. Pharmacological and toxicological studies on domiodol, a new mucolytic agent and expectorant. Arzneimittelforschung. 1983;33(9):1281-6. PMID: 6685509.
3: Esam Z. Protective potential of expectorants against COVID-19. Med Hypotheses. 2020 Sep;142:109844. doi: 10.1016/j.mehy.2020.109844. Epub 2020 May 16. PMID: 32930097.
4: Casali L, Rampulla C, Rossi A. Double-blind clinical trial of domiodol vs S-carboxymethylcysteine in chronic obstructive lung disease. Int J Clin Pharmacol Ther Toxicol. 1982 Nov;20(11):554-7. PMID: 6757153.
5: Finiguerra M, De Martini S, Negri L, Simonelli A. Richerche sugli effetti clinici e funzionali del domiodolo e del sobrerolo nelle broncopeneumopatie ipersecretive [Clinical and functional effects of domiodol and sobrerol in hypersecretory bronchopneumonias]. Minerva Med. 1981 May 26;72(21):1353-60. Italian. PMID: 7015178.
6: Antonelli A, Carraro A, Donati C, Garrubba V. Mucolytic effects of domiodol in tracheostomized patients after total laryngectomy. Double-blind, placebo- controlled, randomized pilot study with four-month follow-up. Arzneimittelforschung. 1992 Feb;42(2):126-32. PMID: 1610421.
7: Ohtsuki T, Takaichi M, Jin Y, Yokoshima T, Kato R. Absorption, distribution, excretion and metabolism of domiodol. Farmaco Prat. 1984 Sep;39(9):291-309. PMID: 6500024.
8: Riva M, Gentili P, Kogi K, Saito T, Cantarelli G, Ravenna F. Domiodol; separation of cis and trans isomers and comparison of their pharmacological activity. Arzneimittelforschung. 1983;33(8):1091-3. PMID: 6685484.
9: Cadel S, Maiorino M, Riunno M, Schiantarelli P. Attivita' secretodinamica di ambroxol nell'animale sperimentale: confronto con bromexina, sobrerolo, domiodolo ed N-acetil-L-cisteina [Secretodynamic activity of ambroxol in the experimental animal: comparison with bromhexine, sobrerol, domiodol and N-acetyl-L-cysteine]. Boll Chim Farm. 1982 Sep;121(9):475-82. Italian. PMID: 7159512.
10: Carissimi M, Riva G, Riva M. Prove di mutagenicità del 2-iodometil-4-ossimetil-1,3-diossolano (cis-trans) Domiodolo - M.G. 13608 [Mutagenicity tests of 2-iodomethyl-4-oxymethyl-1,3-dioxolane (cis- trans)-Domiodol MG 13608]. Boll Chim Farm. 1979 Jul;118(7):407-12. Italian. PMID: 393280.
